Advertisement

CardioVascular and Interventional Radiology

, Volume 42, Issue 9, pp 1230–1239 | Cite as

Focus on Recommendations for the Management of Non-small Cell Lung Cancer

  • Pernelle Lavaud
  • Benjamin Besse
  • Thierry de Baere
  • Frederic Deschamps
  • Sacha Mussot
  • Cécile Le Pechoux
  • Caroline Caramella
  • Olaf Mercier
  • Laura Mezquitta
  • Angela Botticella
  • Pauline Pradere
  • Julien Adam
  • David Planchard
  • Lambros TselikasEmail author
Review
  • 144 Downloads

Epidemiology, Predisposing Factors, Pathology

Lung cancer is the leading cause of cancer mortality worldwide with a total of 2.1 million newly diagnosed cases and 1.8 million related deaths in 2012. The incidence and mortality rates are higher in more developed countries (especially Central and Eastern Europe) than in less developed ones [1].

The median age at diagnosis is around 70 years old. A subset of patients with non-small cell lung cancers (NSCLCs) with molecular alteration presents at a younger age.

Ten most important points of the cancer

1. Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide

2. Tobacco smoking is the main cause of lung cancer

3. Pathological diagnosis with determination of histological type and for advanced diseases molecular characterization are mandatory prior to any treatment

4. The cornerstone of treatment of early stage lung cancer is surgery

5. For unresectable locally advanced NSCLC, concurrent chemoradiotherapy (CRT)...

Notes

Acknowledgements

Authors would like to thank the entire lung committee of Gustave Roussy, and Institut d’Oncologie Thoracique (IOT).

Funding

This study was not supported by any funding.

Compliance with Ethical Standards

Conflict of interest

None.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.  https://doi.org/10.3322/caac.21492.CrossRefGoogle Scholar
  2. 2.
    Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(14):3175–85.  https://doi.org/10.1200/JCO.2005.10.462.CrossRefGoogle Scholar
  3. 3.
    WHO Handbook on Indoor Radon. A public health perspective. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; 2009.Google Scholar
  4. 4.
    Torres-Duran M, Barros-Dios JM, Fernandez-Villar A, Ruano-Ravina A. Residential radon and lung cancer in never smokers. A systematic review. Cancer Lett. 2014;345(1):21–6.  https://doi.org/10.1016/j.canlet.2013.12.010.CrossRefGoogle Scholar
  5. 5.
    Samet JM. Radon and lung cancer. J Natl Cancer Inst. 1989;81(10):745–57.CrossRefGoogle Scholar
  6. 6.
    Brenner DR, Hung RJ, Tsao MS, Shepherd FA, Johnston MR, Narod S, et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer. 2010;10:285.  https://doi.org/10.1186/1471-2407-10-285.CrossRefGoogle Scholar
  7. 7.
    Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Thun MJ, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(18):5626–45.  https://doi.org/10.1158/1078-0432.CCR-09-0376.CrossRefGoogle Scholar
  8. 8.
    National Lung Screening Trial Research T, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.  https://doi.org/10.1056/nejmoa1209120.CrossRefGoogle Scholar
  9. 9.
    Walter JE, Heuvelmans MA, de Jong PA, Vliegenthart R, van Ooijen PMA, Peters RB, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol. 2016;17(7):907–16.  https://doi.org/10.1016/S1470-2045(16)30069-9.CrossRefGoogle Scholar
  10. 10.
    Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34(12):1805–11.  https://doi.org/10.1097/PAS.0b013e3181f7dae3.CrossRefGoogle Scholar
  11. 11.
    Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2018;29(Supplement_4):iv192–237.  https://doi.org/10.1093/annonc/mdy275.CrossRefGoogle Scholar
  12. 12.
    Kim H, Kwon HJ, Park SY, Park E, Chung JH. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget. 2017;8(58):98524–32.  https://doi.org/10.18632/oncotarget.21567.Google Scholar
  13. 13.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer J. 2013;132(2):E37–47.  https://doi.org/10.1002/ijc.27779.CrossRefGoogle Scholar
  14. 14.
    Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(7):1109–21.  https://doi.org/10.1016/j.jtho.2017.04.011.Google Scholar
  15. 15.
    Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The natural history of operable non-small cell lung cancer in the national cancer database. Ann Thorac Surg. 2016;101(5):1850–5.  https://doi.org/10.1016/j.athoracsur.2016.01.077.CrossRefGoogle Scholar
  16. 16.
    Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2017;28(suppl_4):iv1–21.  https://doi.org/10.1093/annonc/mdx222.CrossRefGoogle Scholar
  17. 17.
    Zhang W, Wei Y, Jiang H, Xu J, Yu D. Video-assisted thoracoscopic surgery versus thoracotomy lymph node dissection in clinical stage I lung cancer: a meta-analysis and system review. Ann Thorac Surg. 2016;101(6):2417–24.  https://doi.org/10.1016/j.athoracsur.2015.11.055.CrossRefGoogle Scholar
  18. 18.
    Petrella F, Spaggiari L. The smaller the better: a new concept in thoracic surgery? Lancet Oncol. 2016;17(6):699–700.  https://doi.org/10.1016/S1470-2045(16)30049-3.CrossRefGoogle Scholar
  19. 19.
    Huang X, Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(10):e109979.  https://doi.org/10.1371/journal.pone.0109979.CrossRefGoogle Scholar
  20. 20.
    Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;107(3):403–8.  https://doi.org/10.1016/j.radonc.2013.04.026.CrossRefGoogle Scholar
  21. 21.
    Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013;119(18):3402–10.  https://doi.org/10.1002/cncr.28217.CrossRefGoogle Scholar
  22. 22.
    Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1 non-small cell lung cancer: a national cancer database study. Radiology. 2018;289(3):862–70.  https://doi.org/10.1148/radiol.2018180979.CrossRefGoogle Scholar
  23. 23.
    Lam A, Yoshida EJ, Bui K, Fernando D, Nelson K, Abi-Jaoudeh N. A national cancer database analysis of radiofrequency ablation versus stereotactic body radiotherapy in early-stage non-small cell lung cancer. J Vasc Interv Radiol JVIR. 2018;29(9):1211e1–1217e1.  https://doi.org/10.1016/j.jvir.2018.04.029.CrossRefGoogle Scholar
  24. 24.
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802–9.  https://doi.org/10.1016/S1470-2045(12)70242-5.CrossRefGoogle Scholar
  25. 25.
    Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S. Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(8):1195–200.  https://doi.org/10.1097/JTO.0000000000000576.Google Scholar
  26. 26.
    Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015;114(2):138–47.  https://doi.org/10.1016/j.radonc.2014.11.036.CrossRefGoogle Scholar
  27. 27.
    Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S. Quality of life after stereotactic ablative radiotherapy for early-stage lung cancer: a systematic review. Clin Lung Cancer. 2016;17(5):e141–9.  https://doi.org/10.1016/j.cllc.2015.12.009.CrossRefGoogle Scholar
  28. 28.
    Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. 2017;98(3):622–31.  https://doi.org/10.1016/j.ijrobp.2017.03.010.CrossRefGoogle Scholar
  29. 29.
    Group NM-aC, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77.  https://doi.org/10.1016/s0140-6736(10)60059-1.CrossRefGoogle Scholar
  30. 30.
    Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):29–34.  https://doi.org/10.1200/JCO.2009.24.0333.CrossRefGoogle Scholar
  31. 31.
    Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: cALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(31):5043–51.  https://doi.org/10.1200/JCO.2008.16.4855.CrossRefGoogle Scholar
  32. 32.
    Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017;18(12):1610–23.  https://doi.org/10.1016/S1470-2045(17)30691-5.CrossRefGoogle Scholar
  33. 33.
    Group PM-aT. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005;2005(2):CD002142.  https://doi.org/10.1002/14651858.cd002142.pub2.Google Scholar
  34. 34.
    Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(25):2727–34.  https://doi.org/10.1200/JCO.2015.61.1517.CrossRefGoogle Scholar
  35. 35.
    Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(13):2181–90.  https://doi.org/10.1200/JCO.2009.26.2543.CrossRefGoogle Scholar
  36. 36.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.  https://doi.org/10.1056/NEJMoa1709937.CrossRefGoogle Scholar
  37. 37.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.  https://doi.org/10.1056/NEJMoa1809697.CrossRefGoogle Scholar
  38. 38.
    De Ruysscher D, Wanders R, Hendriks LE, van Baardwijk A, Reymen B, Houben R, et al. Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(12):1958–61.  https://doi.org/10.1016/j.jtho.2018.07.098.Google Scholar
  39. 39.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.  https://doi.org/10.1056/NEJMoa1507643.CrossRefGoogle Scholar
  40. 40.
    Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.  https://doi.org/10.1016/S0140-6736(16)32517-X.CrossRefGoogle Scholar
  41. 41.
    Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.  https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefGoogle Scholar
  42. 42.
    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.  https://doi.org/10.1056/NEJMoa1606774.CrossRefGoogle Scholar
  43. 43.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.  https://doi.org/10.1056/NEJMoa1504627.CrossRefGoogle Scholar
  44. 44.
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(24):3004–11.  https://doi.org/10.1200/JCO.2012.42.3749.CrossRefGoogle Scholar
  45. 45.
    Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.  https://doi.org/10.1056/NEJMoa1801005.CrossRefGoogle Scholar
  46. 46.
    Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.  https://doi.org/10.1056/NEJMoa1716948.CrossRefGoogle Scholar
  47. 47.
    Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.  https://doi.org/10.1056/NEJMoa1810865.CrossRefGoogle Scholar
  48. 48.
    Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein MA, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(18):LBA9000-LBA.  https://doi.org/10.1200/jco.2018.36.18_suppl.lba9000.CrossRefGoogle Scholar
  49. 49.
    Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006;51(3):335–45.  https://doi.org/10.1016/j.lungcan.2005.11.001.CrossRefGoogle Scholar
  50. 50.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3543–51.  https://doi.org/10.1200/JCO.2007.15.0375.CrossRefGoogle Scholar
  51. 51.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.  https://doi.org/10.1056/NEJMoa061884.CrossRefGoogle Scholar
  52. 52.
    Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(1):20–30.  https://doi.org/10.1093/annonc/mds590.CrossRefGoogle Scholar
  53. 53.
    Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(23):2849–53.  https://doi.org/10.1200/jco.2012.48.1911.CrossRefGoogle Scholar
  54. 54.
    Rossi A, Chiodini P, Sun JM, O’Brien ME, von Plessen C, Barata F, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254–62.  https://doi.org/10.1016/S1470-2045(14)70402-4.CrossRefGoogle Scholar
  55. 55.
    Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–40.  https://doi.org/10.1016/S0140-6736(09)61497-5.CrossRefGoogle Scholar
  56. 56.
    Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(23):2895–902.  https://doi.org/10.1200/JCO.2012.47.1102.CrossRefGoogle Scholar
  57. 57.
    Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2004;15(3):419–26.CrossRefGoogle Scholar
  58. 58.
    Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–88.  https://doi.org/10.1016/S0140-6736(11)60780-0.CrossRefGoogle Scholar
  59. 59.
    Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.  https://doi.org/10.1016/S0140-6736(14)60845-X.CrossRefGoogle Scholar
  60. 60.
    Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(10):2095–103.  https://doi.org/10.1200/JCO.2000.18.10.2095.CrossRefGoogle Scholar
  61. 61.
    Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1589–97.  https://doi.org/10.1200/JCO.2004.08.163.CrossRefGoogle Scholar
  62. 62.
    Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3327–34.  https://doi.org/10.1200/JCO.2012.44.2806.CrossRefGoogle Scholar
  63. 63.
    Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(10):1122–8.  https://doi.org/10.1200/JCO.2011.36.8456.CrossRefGoogle Scholar
  64. 64.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.  https://doi.org/10.1016/S1470-2045(11)70393-X.CrossRefGoogle Scholar
  65. 65.
    Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435–44.  https://doi.org/10.1016/S2213-2600(17)30129-7.CrossRefGoogle Scholar
  66. 66.
    Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(8):2240–7.  https://doi.org/10.1158/1078-0432.CCR-12-2246.CrossRefGoogle Scholar
  67. 67.
    Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.  https://doi.org/10.1158/2159-8290.CD-14-0337.CrossRefGoogle Scholar
  68. 68.
    Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40.  https://doi.org/10.1056/NEJMoa1612674.CrossRefGoogle Scholar
  69. 69.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.  https://doi.org/10.1056/NEJMoa1713137.CrossRefGoogle Scholar
  70. 70.
    Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(22):2251–8.  https://doi.org/10.1200/JCO.2017.77.4794.CrossRefGoogle Scholar
  71. 71.
    Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–29.  https://doi.org/10.1016/S0140-6736(17)30123-X.CrossRefGoogle Scholar
  72. 72.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.  https://doi.org/10.1016/S0140-6736(17)30565-2.CrossRefGoogle Scholar
  73. 73.
    Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–9.  https://doi.org/10.1016/S1470-2045(17)30680-0.CrossRefGoogle Scholar
  74. 74.
    Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–39.  https://doi.org/10.1056/NEJMoa1810171.CrossRefGoogle Scholar
  75. 75.
    Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–86.  https://doi.org/10.1016/S1470-2045(17)30339-X.CrossRefGoogle Scholar
  76. 76.
    Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(22):2490–8.  https://doi.org/10.1200/JCO.2016.71.5904.CrossRefGoogle Scholar
  77. 77.
    Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16.  https://doi.org/10.1016/S1470-2045(17)30679-4.CrossRefGoogle Scholar
  78. 78.
    Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7(12):1807–14.  https://doi.org/10.1097/JTO.0b013e3182745948.Google Scholar
  79. 79.
    Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.  https://doi.org/10.1056/NEJMoa1801946.CrossRefGoogle Scholar
  80. 80.
    Pacheco JM, Camidge DR. Antibody drug conjugates in thoracic malignancies. Lung Cancer. 2018;124:260–9.  https://doi.org/10.1016/j.lungcan.2018.07.001.CrossRefGoogle Scholar
  81. 81.
    Duka E, Ierardi AM, Floridi C, Terrana A, Fontana F, Carrafiello G. The role of interventional oncology in the management of lung cancer. Cardiovasc Intervent Radiol. 2017;40(2):153–65.  https://doi.org/10.1007/s00270-016-1495-y.CrossRefGoogle Scholar
  82. 82.
    Yeow KM, Tsay PK, Cheung YC, Lui KW, Pan KT, Chou AS. Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol JVIR. 2003;14(5):581–8.CrossRefGoogle Scholar
  83. 83.
    Gill RR, Murphy DJ, Kravets S, Sholl LM, Janne PA, Johnson BE. Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018;118(7):1170–7.  https://doi.org/10.1002/jso.25241.CrossRefGoogle Scholar
  84. 84.
    Yoon HJ, Lee HY, Lee KS, Choi YL, Ahn MJ, Park K, et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012;265(3):939–48.  https://doi.org/10.1148/radiol.12112613.CrossRefGoogle Scholar
  85. 85.
    Yeow KM, Su IH, Pan KT, Tsay PK, Lui KW, Cheung YC, et al. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest. 2004;126(3):748–54.  https://doi.org/10.1378/chest.126.3.748.CrossRefGoogle Scholar
  86. 86.
    Palussiere J, Chomy F, Savina M, Deschamps F, Gaubert JY, Renault A, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg. 2018;13(1):91.  https://doi.org/10.1186/s13019-018-0773-y.CrossRefGoogle Scholar
  87. 87.
    Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, et al. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer. JAMA Netw Open. 2018;1(4):e181390.  https://doi.org/10.1001/jamanetworkopen.2018.1390.CrossRefGoogle Scholar
  88. 88.
    Tselikas L, de Baere T, Deschamps F, Hakime A, Besse B, Teriitehau C, et al. Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. Eur Radiol. 2017;27(3):1211–7.  https://doi.org/10.1007/s00330-016-4447-7.CrossRefGoogle Scholar
  89. 89.
    Hasegawa T, Kondo C, Sato Y, Inaba Y, Yamaura H, Kato M, et al. Pathologic diagnosis and genetic analysis of a lung tumor needle biopsy specimen obtained immediately after radiofrequency ablation. Cardiovasc Intervent Radiol. 2018;41(4):594–602.  https://doi.org/10.1007/s00270-017-1845-4.CrossRefGoogle Scholar
  90. 90.
    Roux C, Tselikas L, Yevich S, Sandes Solha R, Hakime A, Teriitehau C, et al. Fluoroscopy and cone-beam CT-guided Fixation by internal cemented screw for pathologic pelvic fractures. Radiology. 2018.  https://doi.org/10.1148/radiol.2018181105.Google Scholar
  91. 91.
    de Baere T, Tselikas L, Deschamps F, Soria JC, Marabelle A. Immuno-oncology in cancer care is a fantastic opportunity for interventional oncology: IO4IO (interventional oncology for immuno-oncology) initiative. Cardiovasc Intervent Radiol. 2018;41(6):825–7.  https://doi.org/10.1007/s00270-018-1935-y.CrossRefGoogle Scholar
  92. 92.
    Lin M, Liang SZ, Wang XH, Liang YQ, Zhang MJ, Niu LZ, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65(4):880–7.  https://doi.org/10.1007/s12026-017-8927-x.CrossRefGoogle Scholar
  93. 93.
    Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Can Res. 2012;72(2):430–9.  https://doi.org/10.1158/0008-5472.CAN-11-1782.CrossRefGoogle Scholar
  94. 94.
    Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2017;28(suppl_12):xii33–43.  https://doi.org/10.1093/annonc/mdx683.CrossRefGoogle Scholar
  95. 95.
    Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2018;29(11):2163–74.  https://doi.org/10.1093/annonc/mdy423.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019

Authors and Affiliations

  • Pernelle Lavaud
    • 1
  • Benjamin Besse
    • 1
    • 2
  • Thierry de Baere
    • 2
    • 3
  • Frederic Deschamps
    • 3
  • Sacha Mussot
    • 4
  • Cécile Le Pechoux
    • 5
  • Caroline Caramella
    • 6
  • Olaf Mercier
    • 4
  • Laura Mezquitta
    • 1
  • Angela Botticella
    • 5
  • Pauline Pradere
    • 7
  • Julien Adam
    • 8
  • David Planchard
    • 1
  • Lambros Tselikas
    • 3
    • 9
    Email author
  1. 1.Cancer Medicine DepartmentGustave RoussyVillejuifFrance
  2. 2.Faculté de médecineParis Sud, Paris SaclayOrsayFrance
  3. 3.Interventional RadiologyGustave RoussyVillejuifFrance
  4. 4.Thoracic SurgeryHopital Marie LannelongueLe Plessis RobinsonFrance
  5. 5.Radiation Oncology departmentGustave RoussyVillejuifFrance
  6. 6.Medical Imaging departmentGustave RoussyVillejuifFrance
  7. 7.PneumologyHopital Marie LannelongueLe Plessis RobinsonFrance
  8. 8.Pathology DepartmentGustave RoussyVillejuifFrance
  9. 9.Laboratory of Translational Research in Immunology (LRTI)INSERM U1015VillejuifFrance

Personalised recommendations